Background Asthma affects 350 million people worldwide including 45% to 70% with mild
disease. Treatment is mainly with inhalers containing beta₂‐agonists, typically taken as …

Inhaled corticosteroid (ICS)-containing therapies are the mainstay of pharmacological
management of asthma. They can be administered alone or in combination with a long …

Recent clinical trials of as-needed fixed-dose combination of inhaled corticosteroid
(ICS)/formoterol have provided new evidence that may warrant a reconsideration of current …

Background The stepwise approach to long-term asthma management, which traditionally
incorporates short-acting β2-agonist reliever therapy, has been a core feature of asthma …

Objectives As-needed low-dose combination budesonide-formoterol is recommended by
asthma guidelines in many countries as an alternative to maintenance inhaled …

A large proportion of asthmatic patients are treated with protocols resulting from data
obtained by randomized controlled trials (RCTs) for which they would not have been …

BACKGROUND: The aim of these clinical standards is to aid the diagnosis and
management of asthma in low-resource settings in low-and middle-income countries …

Mild and moderate asthma cover a wide range of asthma presentations, phenotypes and
symptom burden, and account for the majority of people with asthma worldwide. Mild asthma …

Objective To compare bronchodilator response after to salbutamol and
budesonide/formoterol in adults with stable asthma. Methods A double-blind, cross-over …

Overreliance on short-acting β2-agonists (SABA) has been a common feature of asthma
management globally for at least 30 years. However, given the evidence against the long …